Portfolio of three novel immunological therapies based on bispecific T-cell engager technology, each with differentiating performance against multiple cancersEnrollment initiated in first half 2025 for Phase I clinical trials for…
Clearmind Medicine (CMND) is a clinical stage pharmaceutical company with the promising CMND-100 candidate at the front end of its pipeline. CMND-100 is based on the psychoactive compound MEAI, shorthand for the synthetic molecule…
Welcome to the new Small Cap Strategist weblog. The blog got its start in 2008, when website technologies were far simpler than today. Social media was in its infancy. Google's…